Subsequently, EZH2 protein levels, as well as consecutive accumulation of H3K27me3, are reduced, thereby impairing tumor progression, as demonstrated in colon, breast, hepatocellular, and nasopharyngeal cancers, as well as melanoma and glioblastoma [63]. This evidence concerns the gene EZH2 and glioblastoma.